Literature DB >> 33508691

Heroin use is associated with liver fibrosis in the Miami Adult Studies on HIV (MASH) cohort.

Marianna K Baum1, Javier A Tamargo2, Richard L Ehman3, Kenneth E Sherman4, Jun Chen5, Qingyun Liu6, Raul N Mandler7, Colby Teeman8, Sabrina S Martinez9, Adriana Campa10.   

Abstract

BACKGROUND: People who use opioids and people living with HIV (PLWH) are at increased risk for liver-related morbidity and mortality. Although animal models suggest that chronic opioid use may cause liver damage, research in humans is limited. We aimed to determine whether opioid use, particularly heroin, was associated with liver fibrosis.
METHODS: Cross-sectional analysis of 679 participants (295 HIV/HCV uninfected, 218 HIV mono-infected, 87 HCV mono-infected, 79 HIV/HCV coinfected) from the Miami Adult Studies on HIV (MASH) cohort. Liver fibrosis was assessed via magnetic resonance elastography (MRE) on a 3 T Siemens MAGNETOM Prisma scanner.
RESULTS: A total of 120 (17.7 %) participants used opioids. Liver fibrosis was present in 99 (14.6 %) participants and advanced liver fibrosis in 31 (4.6 %). Heroin use (N = 46, 6.8 %) was associated with HCV-seropositivity, smoking, misuse of prescription opioids, and polysubstance use. The use of heroin, but not misuse of prescription opioids, was significantly associated with liver fibrosis (OR = 2.77, 95 % CI: 1.18-6.50) compared to heroin non-users, after adjustment for confounders including excessive alcohol consumption, polysubstance use and HIV and HCV infections. Both HIV and HCV infections were associated with liver fibrosis, whether virally suppressed/undetectable or viremic.
CONCLUSIONS: Heroin use was independently associated with increased risk for liver fibrosis irrespective of the use of other substances and HIV or HCV infections. Both HIV and HCV were associated with higher risk for liver fibrosis, even among those with suppressed or undetectable viral loads. The exact mechanisms for opioid-induced liver fibrosis remain to be fully elucidated.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HIV; Hepatitis C; Liver diseases; Opioids; Substance abuse

Mesh:

Substances:

Year:  2021        PMID: 33508691      PMCID: PMC7889727          DOI: 10.1016/j.drugalcdep.2021.108531

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  45 in total

1.  Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virological response in chronic hepatitis C.

Authors:  M Hedenstierna; A Nangarhari; A El-Sabini; O Weiland; S Aleman
Journal:  J Viral Hepat       Date:  2018-03-08       Impact factor: 3.728

Review 2.  Linearity, Bias, and Precision of Hepatic Proton Density Fat Fraction Measurements by Using MR Imaging: A Meta-Analysis.

Authors:  Takeshi Yokoo; Suraj D Serai; Ali Pirasteh; Mustafa R Bashir; Gavin Hamilton; Diego Hernando; Houchun H Hu; Holger Hetterich; Jens-Peter Kühn; Guido M Kukuk; Rohit Loomba; Michael S Middleton; Nancy A Obuchowski; Ji Soo Song; An Tang; Xinhuai Wu; Scott B Reeder; Claude B Sirlin
Journal:  Radiology       Date:  2017-09-11       Impact factor: 11.105

3.  Morphine sulphate induced histopathological and histochemical changes in the rat liver.

Authors:  Souad H M Bekheet
Journal:  Tissue Cell       Date:  2010-07-23       Impact factor: 2.466

4.  Trends in Any and High-Dose Opioid Analgesic Receipt Among Aging Patients With and Without HIV.

Authors:  William C Becker; Kirsha Gordon; E Jennifer Edelman; Robert D Kerns; Stephen Crystal; James D Dziura; Lynn E Fiellin; Adam J Gordon; Joseph L Goulet; Amy C Justice; David A Fiellin
Journal:  AIDS Behav       Date:  2016-03

Review 5.  Magnetic Resonance Elastography of Liver: Current Update.

Authors:  Safa Hoodeshenas; Meng Yin; Sudhakar Kundapur Venkatesh
Journal:  Top Magn Reson Imaging       Date:  2018-10

6.  Effect of long-term treatment of morphine on enzymes, oxidative stress indices and antioxidant status in male rat liver.

Authors:  Saeed Samarghandian; Reza Afshari; Tahereh Farkhondeh
Journal:  Int J Clin Exp Med       Date:  2014-05-15

Review 7.  2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020.

Authors: 
Journal:  Diabetes Care       Date:  2020-01       Impact factor: 19.112

8.  Human immunodeficiency virus and liver disease: A comprehensive update.

Authors:  Kenneth E Sherman; Marion G Peters; David Thomas
Journal:  Hepatol Commun       Date:  2017-11-06

Review 9.  Opioid epidemic and liver disease.

Authors:  Elizabeth C Verna; Aaron Schluger; Robert S Brown
Journal:  JHEP Rep       Date:  2019-07-09

10.  Liver Fibrosis in HIV Patients Receiving a Modern cART: Which Factors Play a Role?

Authors:  Raphael Mohr; Robert Schierwagen; Carolynne Schwarze-Zander; Christoph Boesecke; Jan-Christian Wasmuth; Jonel Trebicka; Jürgen Kurt Rockstroh
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

View more
  3 in total

1.  Cocaethylene, simultaneous alcohol and cocaine use, and liver fibrosis in people living with and without HIV.

Authors:  Javier A Tamargo; Kenneth E Sherman; Rafick-Pierre Sékaly; Rebeka Bordi; Daniela Schlatzer; Shenghan Lai; Jag H Khalsa; Raul N Mandler; Richard L Ehman; Marianna K Baum
Journal:  Drug Alcohol Depend       Date:  2022-01-12       Impact factor: 4.852

2.  Cocaine and Opioid-Induced Acute Liver Injury: A Rare Case Report.

Authors:  Tsering Dolkar; Abubaker M Hamad; Myat M Han; Myint B Thu; Vijay R Gayam
Journal:  Cureus       Date:  2022-03-29

3.  Contemporary Trends in Hospitalizations for Comorbid Chronic Liver Disease and Substance Use Disorders.

Authors:  Archita P Desai; Marion Greene; Lauren D Nephew; Eric S Orman; Marwan Ghabril; Naga Chalasani; Nir Menachemi
Journal:  Clin Transl Gastroenterol       Date:  2021-06-18       Impact factor: 4.488

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.